In this interactive session, Life Sciences CEOs will explain what their concerns are while evaluating opportunities outside their organizations and maximizing the opportunities inside their organizations. Topics will include:
- How does a CEO incorporate shareholder valuation into the due diligence process?
- How do you measure acceptable risk?
- What due diligence factors do you use in selecting a partner for a collaboration agreement?
Panelists include: George Daniloff, CEO, Carbylan BioSurgery; Dinesh V. Patel, Ph.D., President and CEO, Arête Therapeutics; Tom Moran, Of Counsel, Foley; Jay Sheppard, President and Chief Executive Officer, Relypsa, Inc.; and James A. D. Smith, President and Chief Executive Officer, Genelabs.
Related Insights
June 13, 2025
Energy Current
Key Provisions of the One Big Beautiful Bill (H.R.1) Related to Foreign Ownership and Foreign Supply (FEOC)
Applicable Limitations on Tax Credits under Sections 48E, 45Y, and 45X: The below summary describes provisions in the One Big Beautiful…
June 12, 2025
Foley Career Perspectives
Foley Pride Month Program: Being an Active Ally in Tough Situations
In honor of Pride Month, Foley & Lardner welcomed back PFLAG National for the fifth year in a row to help us continue to advance in our…
June 12, 2025
Legal News: International Trade Enforcement & Compliance
Tips for Avoiding Investigations of Business Fraud in India
Fraud continues to pose significant challenges across industries worldwide. For multinational companies operating in India, the country offers enormous opportunity — but also presents distinct operational and regulatory risks that require executive-level attention and strategic oversight.